RE:RE:RE:RE:RE:RE:More coverage in China I know some have different views but I really wouldn't get too hung up on this. The differences between PDC and ADC are technical, the basic principle is the same. Even on those technical differences what ultimately matters for each drug is proving the specifics for your drug with empirical data not some general hypothetical rules.
ESMO is happening next week, the biggest EU cancer conference. Just a flick thru the industrial symposia shows ADCs have a solid position in cancer drug development. The people that matter will have no problem extending what they hear there to PDC.
https://www.esmo.org/meetings/esmo-congress-2021/programme
All the company has to do is prove the potential of Sortilin and their Sortilin-targeting drugs. The basic principles of PDC are not the challenge.
SPCEO1 wrote: It will really help TH's stock price if PDC become the next "big thing" in drug research and if their phasw 1a results are impressive. TH could be seen as the leader in this new area if that is how it plays out and that would defintely help the share price a lot. Let's hope everything falls nicely into place in the months ahead.
scarlet1967 wrote: It seems like there are more coverage of the targeted drug delivery now, all these frequent articles are new, never came across them before!
Recently, another biomedical company called Theratechnologies also announced the research progress of two PDCs in its R&D pipeline. Up to now, two PDC products have been approved worldwide, and a number of PDC products have entered the clinical stage. At present, this field has attracted international pharmaceutical giants including Novartis, AstraZeneca, Roche, etc. to deploy one after another. Domestic innovative drug companies such as Sheng Nuoji Pharmaceutical and Mainstream Biology have also begun to conduct PDC research and development.
Based on its versatility and advantages, PDC is a research field with broad development prospects. As more innovative biomedical companies join, PDC drugs are expected to achieve rapid development.
https://m.jrj.com.cn/madapter/stock/2021/09/07085333396635.shtml